Serplulimab Approved by NMPA for Perioperative Gastric Cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy
Dr. Jason Zhu, Executive Director and CEO of Henlius, stated:“The approval of serplulimab for perioperative gastric cancer marks another major milestone for Henlius as we continue to drive innovation based on ‘first principles’ and deepen our presence in gastrointestinal oncology. Centered on patient needs, this new post-operative chemotherapy-free regimen not only underscores our strong expertise in tumor immunotherapy, but also brings new hope for cure to patients undergoing perioperative treatment for gastric cancer. Looking ahead, we will continue to unlock the clinical potential of our innovative pipeline and accelerate our Globalization 2.0 strategy, with the goal of delivering high-quality innovative biologic medicines to benefit patients in China and around the world.”
Share:
More News
Reagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: “The dosing of patients marks an important milestone for Anocca, and demonstrates our ability to develop, manufacture and clinically deploy precision TCR-T cell therapy products. The novel ANOC-001 clinical candidate was developed with Anocca’s proprietary analytical platform that maps targets
“The clinical experience in 81 patients validates both EBTATE and the broader Evans Blue platform,” said Chris Pak, Chairman and Chief Executive Officer of MTTI. “By improving tumor delivery and retention while requiring only approximately 12.5% of the cumulative radioactivity administered in current standard-of-care PRRT, the platform has the potential
Leslie Chong, Managing Director and CEO of Imugene, commented: “FDA Fast Track Designation for both CLL/SLL and MZL reflects the meaningful clinical activity we are seeing with azer-cel across multiple B-cell malignancies. For patients who have exhausted standard treatment options in these indications, we believe azer-cel represents a genuinely promising
“Our approach to innovation in cancer care is grounded in real-world impact, both advancing treatment and improving how care is delivered,” said Olivier Nataf, Global Head of Oncology at Sanofi. “Sarclisa, which has been prescribed to nearly 70,000 patients worldwide, already brings a well-established safety and efficacy profile across the